NZ706909A - Novel α4ß7 peptide dimer antagonists - Google Patents

Novel α4ß7 peptide dimer antagonists

Info

Publication number
NZ706909A
NZ706909A NZ706909A NZ70690913A NZ706909A NZ 706909 A NZ706909 A NZ 706909A NZ 706909 A NZ706909 A NZ 706909A NZ 70690913 A NZ70690913 A NZ 70690913A NZ 706909 A NZ706909 A NZ 706909A
Authority
NZ
New Zealand
Prior art keywords
novel
peptide dimer
antagonists
dimer antagonists
binding
Prior art date
Application number
NZ706909A
Other languages
English (en)
Inventor
Ashok Bhandari
Dinesh V Patel
Larry C Mattheakis
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of NZ706909A publication Critical patent/NZ706909A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ706909A 2012-10-11 2013-10-11 Novel α4ß7 peptide dimer antagonists NZ706909A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261712722P 2012-10-11 2012-10-11
US201361807714P 2013-04-02 2013-04-02
US14/050,349 US9273093B2 (en) 2012-10-11 2013-10-10 α4β7 peptide dimer antagonists
PCT/US2013/064439 WO2014059213A1 (en) 2012-10-11 2013-10-11 NOVEL α4ß7 PEPTIDE DIMER ANTAGONISTS

Publications (1)

Publication Number Publication Date
NZ706909A true NZ706909A (en) 2018-11-30

Family

ID=50477907

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ706909A NZ706909A (en) 2012-10-11 2013-10-11 Novel α4ß7 peptide dimer antagonists

Country Status (13)

Country Link
US (3) US9273093B2 (Direct)
EP (1) EP2906584B1 (Direct)
JP (2) JP6480865B2 (Direct)
KR (1) KR20150084808A (Direct)
CN (1) CN105102470A (Direct)
AU (2) AU2013329135B2 (Direct)
CA (1) CA2888479A1 (Direct)
HK (1) HK1213583A1 (Direct)
IL (1) IL238123A0 (Direct)
IN (1) IN2015DN03039A (Direct)
NZ (1) NZ706909A (Direct)
SG (2) SG11201502812WA (Direct)
WO (1) WO2014059213A1 (Direct)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
WO2014153002A1 (en) 2013-03-14 2014-09-25 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
PT2968443T (pt) 2013-03-15 2021-12-28 Protagonist Therapeutics Inc Análogos de hepcidina e seus usos
US20140294901A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
KR102302634B1 (ko) 2013-09-13 2021-09-14 더 스크립스 리서치 인스티튜트 변형된 치료제 및 이의 조성물
EP3082797A4 (en) 2013-12-18 2017-12-13 The California Institute for Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
SG10201810321PA (en) * 2014-05-16 2018-12-28 Protagonist Therapeutics Inc α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
BR112017001010A2 (pt) 2014-07-17 2017-11-14 Protagonist Therapeutics Inc inibidores peptídicos orais do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias intestinais
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
JP2017535527A (ja) 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス， インコーポレイテッド 新規のα４β７ペプチド単量体及び二量体拮抗薬
US20190000928A1 (en) * 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017041001A2 (en) 2015-09-04 2017-03-09 The California Institute For Biomedical Research Insulin immunoglobulin fusion proteins
US11634470B2 (en) * 2015-10-23 2023-04-25 Jai Prakash Integrin binding peptides and uses thereof
JP6961586B2 (ja) * 2015-11-11 2021-11-05 ジーランド ファーマ エイ／エス α４β７インテグリンを標的とする環状ペプチド
WO2017100540A2 (en) 2015-12-09 2017-06-15 The California Institute For Biomedical Research Relaxin immunoglobulin fusion proteins and methods of use
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
ES2992761T3 (en) 2016-02-04 2024-12-17 Scripps Research Inst Humanized anti-cd3 antibodies, conjugates and uses thereof
CN115925790A (zh) * 2016-03-23 2023-04-07 领导医疗有限公司 用于合成α4β7肽拮抗剂的方法
US11111273B2 (en) 2016-11-11 2021-09-07 Zealand Pharma A/S Cyclic peptides multimers targeting alpha-4-beta-7 integrin
JP7274425B2 (ja) * 2017-05-10 2023-05-16 ジーランド ファーマ アクティーゼルスカブ α４β７インテグリンを標的とするホモデチック環状ペプチド
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
US11753443B2 (en) 2018-02-08 2023-09-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3135024A1 (en) * 2019-03-28 2020-10-01 Protagonist Therapeutics, Inc. Methods for synthesizing .beta.-homoamino acids
CN116082455A (zh) 2019-07-10 2023-05-09 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
MX2022008486A (es) * 2020-01-10 2022-10-13 Protagonist Therapeutics Inc MÉTODOS PARA TRATAR ENFERMEDADES INTESTINALES INFLAMATORIAS CON ANTAGONISTAS DE INTEGRINA A4ß7.
CR20220332A (es) 2020-01-15 2022-11-28 Janssen Biotech Inc Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
EP4090669A4 (en) 2020-01-15 2024-11-20 Janssen Biotech, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
JP2024522196A (ja) 2021-06-09 2024-06-11 ザ スクリプス リサーチ インスティテュート 長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法
PE20240595A1 (es) 2021-07-14 2024-03-21 Janssen Biotech Inc Inhibidores peptidicos lipidicos del receptor de iinterleucina-23

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4724229A (en) * 1986-09-30 1988-02-09 Smithkline Beckman Corporation Arg-arg-arg-vasopressin antagonists
EP0578728B1 (en) * 1991-04-05 1998-07-01 Genentech, Inc. PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIIIa
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5990084A (en) 1996-04-19 1999-11-23 Novo Nordisk A/S Compounds with growth hormone releasing properties
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
AU8399998A (en) * 1997-07-11 1999-02-08 Innerdyne, Inc. Methods and systems for preparing and sealing radiation delivery structures
US6818617B1 (en) 1997-08-15 2004-11-16 Temple University- Of The Commonwealth System Of Higher Education EC-3, an inhibitor of α4β1 and α4β7 integrins
WO1999026615A1 (en) 1997-11-24 1999-06-03 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
JP2002524108A (ja) * 1998-07-28 2002-08-06 インナーダイン， インコーポレイテッド 吸収性近接照射療法および化学療法送達デバイスならびに方法
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
AUPP616598A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Auxiliary for amide bond formation
AUPP660698A0 (en) 1998-10-21 1998-11-12 University Of Queensland, The A method of protein engineering
CA2369728A1 (en) 1999-04-12 2000-10-19 Aventis Pharma Limited Substituted bicyclic heteroaryl compounds as integrin antagonists
WO2001068586A2 (en) 2000-03-14 2001-09-20 Novartis Ag α4β1 AND α4β7 INTEGRIN INHIBITORS
DE10107707A1 (de) 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonisten für alpha¶4¶beta¶7¶-Integrin
AUPS039702A0 (en) 2002-02-08 2002-03-07 University Of Queensland, The Common protein surface shapes and uses therefor
AU2003301059A1 (en) 2002-12-18 2004-07-22 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
US20070032417A1 (en) 2002-12-24 2007-02-08 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
CN107090025A (zh) 2003-11-05 2017-08-25 达纳-法伯癌症研究所股份有限公司 稳定的α螺旋肽及其用途
WO2005064345A2 (en) 2003-12-19 2005-07-14 Applera Corporation Methods and systems for protein and peptide evidence assembly
DE602005026779D1 (de) 2004-01-09 2011-04-21 Pfizer ANTIKÖRPER GEGEN MAdCAM
US8536140B2 (en) 2004-03-12 2013-09-17 Mti Meta Tech Inc. Methods for treating inflammatory bowel disease
JP2008504239A (ja) 2004-06-24 2008-02-14 ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 複合体およびその治療的使用
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006058539A2 (en) 2004-11-30 2006-06-08 Gastrotech Pharma A/S Growth hormone secretagogue receptor 1a ligands
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
US9193790B2 (en) 2006-12-07 2015-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CA2683145C (en) 2007-04-27 2018-06-12 Katherine E. Lewis Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009002947A2 (en) * 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
EP2288621A4 (en) 2007-07-06 2012-01-04 Valorisation Hsj Soc En Commandite IL23 RECEPTOR ANTAGONISTS AND THEIR USE
WO2009039185A1 (en) * 2007-09-17 2009-03-26 The Trustees Of Columbia University In The City Of New York Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation
WO2009045536A2 (en) 2007-10-05 2009-04-09 The University Of North Carolina At Chapel Hill Receptor targeted oligonucleotides
DE102009007381A1 (de) * 2009-01-29 2010-08-05 Amp-Therapeutics Gmbh & Co. Kg Antibiotische Peptide
US8999935B2 (en) 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
EP2418213B1 (en) * 2009-04-08 2014-11-19 Takeda Pharmaceutical Company Limited Neuromedin u derivative
US9523073B2 (en) 2010-03-31 2016-12-20 Medical Diagnostic Laboratories, Llc Elisa for a naturally-occurring soluble truncated form of IL-23 receptor
US9243034B2 (en) 2011-01-27 2016-01-26 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9169292B2 (en) 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
CN104011066A (zh) 2011-12-09 2014-08-27 加利福尼亚大学董事会 经修饰的微型铁调素肽及其使用方法
US20150157692A1 (en) 2012-05-23 2015-06-11 The University Of Chicago Methods of treating obesity
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
KR20150127622A (ko) 2013-02-15 2015-11-17 에스알엑스 카디오, 엘엘씨 혈청 저밀도 지단백질 （ｌｄｌ） 수준을 조절하기 위한 전구단백질 컨버타제 서브틸리신/켁신 유형 9 （ｐｃｓｋ９） 알로스테릭 결합 리간드
US20140294902A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
US20140294901A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
RS60180B1 (sr) 2013-06-24 2020-06-30 Canbas Co Ltd Kombinovana upotreba peptida i peptidomimetika i tretman subpopulacija pacijenata obolelih od kancera

Also Published As

Publication number Publication date
IL238123A0 (en) 2015-05-31
US20160368966A1 (en) 2016-12-22
US20140193465A1 (en) 2014-07-10
IN2015DN03039A (Direct) 2015-10-02
EP2906584B1 (en) 2019-11-20
JP2019001825A (ja) 2019-01-10
AU2013329135A1 (en) 2015-04-30
JP6480865B2 (ja) 2019-03-13
JP2015533833A (ja) 2015-11-26
EP2906584A4 (en) 2016-06-15
CN105102470A (zh) 2015-11-25
US9273093B2 (en) 2016-03-01
AU2013329135B2 (en) 2018-02-01
US20190248870A1 (en) 2019-08-15
SG10201702979SA (en) 2017-05-30
EP2906584A1 (en) 2015-08-19
SG11201502812WA (en) 2015-05-28
CA2888479A1 (en) 2014-04-17
HK1213583A1 (zh) 2016-07-08
WO2014059213A1 (en) 2014-04-17
KR20150084808A (ko) 2015-07-22
AU2018201599A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
NZ706909A (en) Novel α4ß7 peptide dimer antagonists
HK1221233A1 (zh) 新型α4β7肽二聚体拮抗剂
SG10201810321PA (en) α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
IN2015MN00139A (Direct)
MX391184B (es) ANTAGONISTAS DE MONOMÉRICOS Y DIMÉRICOS PEPTÍDICOS DE a4ß7 NOVEDOSOS.
HK1206636A1 (zh) 用於制备肿瘤相关蛋白和多肽的修饰的多核苷酸
MX384191B (es) Molecula de union al antigeno especifico para el tejido objetivo.
MX2013012844A (es) Secuencias de aminoacidos dirigidas contra il-17a, il-17f y/o il-17a/f y polipeptidos que comprenden las mismas.
NZ629394A (en) Synthetic brassica-derived chloroplast transit peptides
BR112013005699A2 (pt) moléculas de ligação a 4-1bb
MX359258B (es) Polipeptidos de enlace biparatopicos para cxcr2 y usos de los mismos.
EA201690461A1 (ru) Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
IN2014DN08481A (Direct)
IN2015DN00636A (Direct)
PH12015501687A1 (en) Novel binding proteins from pcsk9
IN2014DN08668A (Direct)
EA033145B1 (ru) Применение полученных из pedf пептидов в стимуляции регенерации мышцы, регенерации сухожилия или артериогенеза
WO2013028334A3 (en) Use of small molecules in methods for purification of biomolecules
IN2014DN03152A (Direct)
PL401631A1 (pl) Nowe kompleksy rutenu, sposób ich wytwarzania oraz ich zastosowanie
WO2011034659A3 (en) Advantageous mu-opiate receptor peptide compounds
CY1119470T1 (el) Γαλακταγωγες συνθεσεις με βαση φωσφατιδυλοσερινη
IN2014DN10328A (Direct)
MX2016008478A (es) Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer.
SA517390221B1 (ar) Igf-1r الجسم المضاد لـ واستخدامه في تشخيص سرطان

Legal Events

Date Code Title Description
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2020 BY CPA GLOBAL

Effective date: 20190829

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2021 BY CPA GLOBAL

Effective date: 20200827

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2022 BY CPA GLOBAL

Effective date: 20210827

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2023 BY COMPUTER PACKAGES INC

Effective date: 20220930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2024 BY COMPUTER PACKAGES INC

Effective date: 20230917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2025 BY COMPUTER PACKAGES INC

Effective date: 20240917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2026 BY COMPUTER PACKAGES INC

Effective date: 20250917